natgillin/translations-raw huggingface dataset:
synonyms: familial atypical mole-malignant melanoma syndrome, FAMMM; dysplastic naevus syndrome, DNS; B-K mole syndrome; CMM2 MIM #155601) and/or an - individual history of basal cell carcinoma, squamous cell carcinoma (inclusive of carcinoma in situ, e.g. Bowen's disease), Merkel cell carcinoma, or other malignant or premalignant skin lesions.
- z melanomom v osebni ali družinski anamnezi (vključno z melanomom in situ, npr. maligni lentigo) ali domnevno ali potrjeno občutljivostjo za kožni melanom (CMM1, MIM #155600, sinonimi: družinski sindrom atipičnega kožnega znamenja/malignega melanoma, FAMMM; sindrom displastičnega nevusa, DNS; sindrom kožnega znamenja B-K; CMM2 MIM #155601)
Palpitations Tachycardia
Srčne bolezni palpitacije, tahikardija
EPP patients with fair skin may be more likely to request treatment and are more prone to developing UV light-associated skin changes, including cancer; - detect and monitor changes in pigmentary lesions, thus allowing early detection of melanoma.
- odkrivanje in spremljanje sprememb pigmentnih lezij, kar omogoča zgodnje odkrivanje melanoma.
Upper respiratory tract infection
− okužbe zgornjih dihal (prehladi).
NAME OF THE MEDICINAL PRODUCT SCENESSE 16 mg implant
IME ZDRAVILA Scenesse 16 mg implantat
If you get any side effects, talk to your doctor.
Če opazite katerega koli neželenih učinkov, se posvetujte z zdravnikom.
Name and address of the manufacturer(s) responsible for batch release
A. PROIZVAJALEC, ODGOVOREN ZA SPROŠČANJE SERIJ Ime in naslov proizvajalca, odgovornega za sproščanje serij
- Keep this leaflet.
mehurčkasti izpuščaj,
Uncommon unspecified (incl cysts and polyps) Blood and lymphatic system disorders
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
SCENESSE 16 mg implant afamelanotide
Navodilo za uporabo Scenesse 16 mg implantat afamelanotid
In most cases these adverse reactions are reported to be mild in severity.
Poročali so, da je bila resnost večine teh neželenih učinkov blaga.
Reproductive system and breast disorders
Bolezni krvi in limfatičnega sistema levkopenija
- With the bevel of the needle facing upwards, insert the catheter laterally 1.5 to 2 cm into the subcutaneous layer at a 30 to 45 degree angle to the skin surface in one continuous flowing movement.
- Kateter z enim neprekinjenim gibom lateralno vstavite 1,5 do 2 cm v subkutano plast pod kotom
NAME OF THE MEDICINAL PRODUCT SCENESSE 16 mg implant afamelanotide
IME ZDRAVILA Scenesse 16 mg implantat afamelanotid
Pain in extremity Muscle spasm Musculoskeletal pain Musculoskeletal stiffness Joint stiffness Groin pain
mišični spazem, mišično-skeletna bolečina,
- Inflamed lips, lip swelling, colouration on lip, gum pain, toothache, discoloured gums, reduced sense of touch in mouth, lip discolouration, tongue discolouration
− vnetje ustnic, otekanje ustnic, obarvanje ustnic, bolečina v dlesni, zobobol, sprememba barve dlesni, zmanjšan občutek dotika v ustih, sprememba barve ustnic, sprememba barve jezika;
Pre- and post-natal development of Sprague-Dawley rats was not affected at exposures of about 135-times the human exposure (based on Cmax).
Pri izpostavljenosti, približno 135 krat večji kot pri človeku (na podlagi Cmax), ni bilo nobenih učinkov na razvoj podgan vrste Sprague-Dawley pred skotitvijo in po njej.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION SCENESSE 16 mg implant afamelanotide
IME ZDRAVILA IN POT(I) UPORABE Scenesse 16 mg implantat afamelanotid subkutana uporaba
Decreased appetite Hypercholesterolaemia Increased appetite
Presnovne in prehranske motnje zmanjšan tek hiperholesterolemija,
- Pain, swelling around site of implantation, bruising at injection site, irritation at injection site, enlargement at implant site, itching at implant site, implant falling out, change in colour of skin at implant site
− bolečina, otekanje na mestu vsaditve, podplutbe na mestu injiciranja, draženje na mestu injiciranja, povečanje na mestu vsaditve, srbenje na mestu vsaditve, izpad implantata,
Gastrointestinal infection Gastroenteritis Folliculitis
Infekcijske in parazitske bolezni okužba zgornjih dihal gripa, okužba prebavil, gastroenteritis,
Pregnancy and breastfeeding
− driska in bruhanje;
The implant is inserted directly under the skin folds on your waist or abdomen in an area known as the supra-iliac crest.
Implantat se vstavi neposredno pod kožno gubo na pasu ali trebuhu, tj.
Gingival discolouration
zmanjšan libido
Gastroesophageal reflux disease
Žilne bolezni zardevanje,
Alanine aminotransferase increased
povečan tek
Arrange for an early appointment with your porphyria specialist if pigmented lesions like moles grow or if other growing, non-healing, weeping, plaque-like, wart-like, or ulcerated lesions appear.
Če se pigmentne lezije, kot so kožna znamenja, večajo ali če se pojavijo druge večajoče se ploščam podobne, bradavicam podobne ali ulcerozne kožne spremembe z izcedkom, ki se ne celijo, se naročite na zgodnji obisk pri specialistu za porfirijo.
Musculoskeletal and connective tissue disorders
mišično-skeletna togost, togost sklepa,
• Methods to prevent or minimise application errors and application site reactions Registry information sheet shall contain the following key messages:
• pomembnost ohranjevanja aseptičnih pogojev; • metode za preprečevanje ali zmanjševanje napak pri vsaditvi in reakcij na mestu vsaditve.
Abdominal discomfort Toothache
Bolezni sečil cistitis
Oedema peripheral Oedema mucosal Pain
Občasni folikulitis, kandidoza, nazofaringitis
Presbyopia
hipertenzija
Blood cholesterol increased Blood glucose increased Blood iron decreased Blood pressure diastolic increased
zvišan diastolični krvni tlak,
Melanocytic naevus Pigmentation disorder Skin discolouration Skin hyperpigmentation Ephelides
Bolezni kože in podkožja eritem, melanocitni nevus, motnja pigmentacije, sprememba barve kože, hiperpigmentacija kože, efelide, pruritus lichen planus,
Menorrhagia Dysmenorrhoea Breast tenderness Menstruation irregular Vaginal discharge Libido decreased
Motnje reprodukcije in dojk menoragija, dismenoreja,
Eyelid oedema Ocular hyperaemia Dry eye
Očesne bolezni edem očesne veke, očesna hiperemija,
Migraine Dizziness Lethargy Somnolence
slaba kakovost spanja, disgevzija
Lichen planus Rash vesicular Pruritus generalised Rash
generalizirani pruritus,
Abdominal pain Abdominal pain upper Diarrhoea
Občasni zobobol, abdominalni simptom,
QUALITATIVE AND QUANTITATIVE COMPOSITION The implant contains 16 mg of afamelanotide.
Implantat vsebuje 16 mg afamelanotida.
- Mark 1.5 to 2 cm on the catheter shaft using surgical ink.
- S kirurškim črnilom označite kanal katetra med 1,5 in 2 cm.
Eye disorders
− vročinski oblivi;
Flushing Hot flush
vročinski oblivi hematom,
Injury, poisoning and procedural complications
Poškodbe in zastrupitve in zapleti pri posegih zapleti na rani, odprta rana, padec, navzea med postopkom
The European Commission granted a marketing authorisation valid throughout the European Union for BindRen on 21 January 2013.
Evropska komisija je dovoljenje za promet z zdravilom BindRen, veljavno po vsej Evropski uniji, odobrila dne 21. januarja 2013.
This leads to hyperphosphataemia, which, in the long term, can cause complications such as heart and bone disease.
To vodi do hiperfosfatemije, ki lahko dolgoročno povzroči zaplete, na primer bolezni srca in kosti.
The full EPAR for BindRen can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo BindRen je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
It is available as tablets (1 g) and as granules (sachets containing 2 or 3 g).
Na voljo je v obliki tablet (1 g) in zrnc (vrečke vsebujejo 2 ali 3 g).
All patients were on dialysis and received BindRen for three months.
Vsi bolniki so bili na dializi in prejemali zdravilo BindRen tri mesece.
This is a summary of the European public assessment report (EPAR) for BindRen.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo BindRen.
Other information about BindRen
Druge informacije o zdravilu BindRen
The effects of BindRen were first tested in experimental models before being studied in humans.
Učinki zdravila BindRen so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
For more information about treatment with BindRen, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom BindRen preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The dose of BindRen should be adjusted every two to three weeks to a maximum of 15 g per day to reach an acceptable level of phosphate in the blood, which should then be monitored regularly.
Odmerek zdravila BindRen je treba prilagoditi vsaka dva do tri tedne do največ 15 g na dan, da se doseže sprejemljiva raven fosfatov v krvi, ki jo je nato treba redno spremljati.
Patients with severe kidney disease cannot eliminate phosphate from their bodies.
Bolniki z resnim obolenjem ledvic iz telesa ne morejo izločati fosfatov.
There were no major safety concerns and the overall safety profile was similar to that of other phosphate binders, as the side effects affected mainly the gut and resolved by themselves.
Opazil ni nobenih večjih varnostnih zadržkov, splošni varnostni profil pa je podoben drugim vezalcem fosfatov, saj so neželeni učinki večinoma povezani z črevesjem in samodejno izzvenijo.
The recommended starting dose of BindRen is 6 to 9 g per day, taken in three equally divided doses together with or immediately after meals.
Priporočeni začetni odmerek zdravila BindRen je 6 do 9 g na dan, ki se razdeli v tri enake odmerke in se jemlje hkrati z obrokom ali takoj po njem.
When taken with meals, colestilan attaches to phosphate from food within the gut, preventing it from being absorbed into the body.
Če se jemlje hkrati z obrokom, se v črevesju veže na fosfate iz hrane, s čimer preprečuje njihovo absorpcijo v telo.
In clinical trials, around 3 in 10 patients experienced at least one side effect.
V kliničnih preskušanjih so se pri vsaj enem bolniku od treh pojavili neželeni učinki.
All studies looked at the change in the average amount of phosphate in the blood after three months.
V vseh študijah so opazovali spremembo povprečnih ravni fosfatov v krvi po treh mesecih.
BindRen must not be used in people who are hypersensitive (allergic) to colestilan or any of the other ingredients.
Zdravila BindRen ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) kolestilan ali katero koli drugo sestavino zdravila.
What benefit has BindRen shown during the studies?
Kakšne koristi je zdravilo BindRen izkazalo med študijami?
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for BindRen.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo BindRen, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The third study also showed that BindRen was more effective than placebo when used at doses of 6, 9, 12 and 15 g/day: compared with placebo, the reduction in blood phosphate levels seen with BindRen was 0.16, 0.21, 0.19 and 0.37 mmol/l respectively.
Tretja študija je prav tako pokazala, da je zdravilo BindRen učinkovitejše od placeba, kadar se uporablja v odmerkih 6, 9, 12 ali 15 g na dan: in sicer je bilo v primerjavi s placebom znižanje ravni fosfatov v krvi po uporabi zdravila BindRen glede na gornje odmerke 0,16 mmol/l, 0,21 mmol/l, 0,19 mmol/l in 0,37 mmol/l.
BindRen was investigated in two main studies involving 273 adults with long-term kidney disease and hyperphosphataemia.
Zdravilo BindRen so raziskali v dveh glavnih študijah, v katerih je sodelovalo 273 odraslih z dolgotrajnim obolenjem ledvic in hiperfosfatemijo.
What is the risk associated with BindRen?
Kakšna tveganja so povezana z zdravilom BindRen?
The CHMP noted that treatment with BindRen has a beneficial effect in lowering phosphate levels.
CHMP je ugotovil, da zdravilo BindRen pozitivno vpliva na zniževanje ravni fosfatov.
It is used in patients on haemodialysis (using a blood filtration machine) or peritoneal dialysis (where fluid is pumped into the abdomen and an internal body membrane filters the blood).
Uporablja se pri bolnikih, ki prejemajo hemodializo (z uporabo naprave za filtriranje krvi) ali peritonealno dializo (pri čemer se tekočina črpa v trebuh, notranja telesna membrana pa filtrira kri).
BindRen is a medicine that contains the active substance colestilan.
BindRen je zdravilo, ki vsebuje zdravilno učinkovino kolestilan.
A third main study involving 642 patients compared the effects of giving BindRen at various doses with placebo (a dummy treatment) for three months.
V tretji glavni študiji so tri mesece pri 642 bolnikih primerjali učinke dajanja zdravila BindRen v različnih odmerkih z učinki placeba (zdravila brez zdravilne učinkovine).
The first two studies showed that BindRen was effective at controlling blood phosphate levels in patients with long-term kidney disease who were on dialysis.
Prvi dve študiji sta pokazali, da je zdravilo BindRen učinkovito pri nadzoru ravni fosfatov v krvi pri bolnikih z dolgotrajnim obolenjem ledvic, ki so na dializi.
The CHMP decided that BindRen's benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila BindRen večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
For the full list of all side effects reported with BindRen, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila BindRen, glejte navodilo za uporabo.
The most frequently reported side effects were nausea (feeling sick), dyspepsia (heartburn) and vomiting.
Drugi pogosto opaženi učinki so bili navzeja (slabost), dispepsija (zgaga) in bruhanje.
In the first study, an average dose of 11.5 g of BindRen reduced the blood phosphate level by 0.36 mmol/l on average after three months.
V prvi študiji je povprečni odmerek 11,5 g zdravila BindRen v povprečju znižal ravni fosfatov v krvi za 0,36 mmol/l po treh mesecih.
BindRen is used to control hyperphosphataemia (high blood phosphate levels) in adults with long-term kidney disease who are on dialysis (a blood clearance technique).
Zdravilo BindRen se uporablja za uravnavanje hiperfosfatemije (zvišane ravni fosfatov v krvi) pri odraslih bolnikih z dolgotrajnim obolenjem ledvic, ki so na dializi (tehniki čiščenja krvi).
Similarly in the second study, an average dose of 13.1 g of BindRen resulted in a reduction of the blood phosphate level by 0.50 mmol/l on average after three months.
Podobno je v drugi študiji povprečni odmerek 13,1 g zdravila BindRen v povprečju znižal ravni fosfatov v krvi za 0,50 mmol/l po treh mesecih.
Why has BindRen been approved?
Zakaj je bilo zdravilo BindRen odobreno?
The most serious reported side effects with BindRen were gastrointestinal haemorrhage (bleeding in the stomach and gut) and constipation.
Najresnejša neželena učinka, opažena pri uporabi zdravila BindRen, sta bila krvavenje v črevesju in trebuhu ter zaprtje.
It must not be used in people with bowel obstruction (a blockage in the gut).
Ne sme se uporabljati pri ljudeh, ki imajo zaporo črevesa.
How has BindRen been studied?
Kako je bilo zdravilo BindRen raziskano?
The active substance in BindRen, colestilan, is a phosphate binder.
Zdravilna učinkovina zdravila BindRen je fosfatni vezalec kolestilan.
What is BindRen used for?
Za kaj se zdravilo BindRen uporablja?
How is BindRen used?
Kako se zdravilo BindRen uporablja?
Patients should keep to their prescribed low phosphate diets.
Bolniki se morajo držati tudi diete, ki znižuje količino fosfatov v krvi.
What is BindRen?
Kaj je zdravilo BindRen?
How does BindRen work?
Kako zdravilo BindRen deluje?
Further information on Biktarvy can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Nadaljnje informacije o zdravilu Biktarvy so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Side effects were similar to those of medicines of the same class.
Neželeni učinki so bili podobni kot pri drugih zdravilih iz istega razreda.
What measures are being taken to ensure the safe and effective use of Biktarvy?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Biktarvy?
The European Medicines Agency therefore decided that Biktarvy's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Biktarvy večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
The benefits of Biktarvy in the treatment of HIV infection were investigated in four main studies.
Koristi zdravila Biktarvy pri zdravljenju okužbe z virusom HIV so raziskali v štirih glavnih študijah.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Biktarvy have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Biktarvy upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Other information about Biktarvy
Druge informacije o zdravilu Biktarvy
What are the risks associated with Biktarvy?
Kakšna tveganja so povezana z zdravilom Biktarvy?
As for all medicines, data on the use of Biktarvy are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Biktarvy stalno spremljajo.
What is Biktarvy and what is it used for?
Kaj je zdravilo Biktarvy in za kaj se uporablja?
Why is Biktarvy authorised in the EU?
Zakaj je bilo zdravilo Biktarvy odobreno v EU?
Side effects reported with Biktarvy are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Biktarvy, se skrbno ovrednotijo in po potrebi se lahko sprejmejo ukrepi za zaščito bolnikov.
It is only used in patients where the virus has not developed resistance to a class of HIV medicines called integrase inhibitors, or to tenofovir or emtricitabine.
Uporablja se le pri bolnikih, pri katerih virus ni razvil odpornosti na razred zdravil za zdravljenje okužb z virusom HIV, imenovanih zaviralci integraze, ali na tenofovir ali emtricitabin.
An overview of Biktarvy and why it is authorised in the EU
Pregled zdravila Biktarvy in zakaj je odobreno v EU
Biktarvy contains three active substances which work in different ways against HIV:
Zdravilo Biktarvy vsebuje tri učinkovine, ki na različne načine delujejo proti virusu HIV:
Biktarvy was shown to be as effective as comparator antiviral medicines.
Zdravilo Biktarvy se je pokazalo za enako učinkovito kot primerjalna protivirusna zdravila.
What benefits of Biktarvy have been shown in studies?
Kakšne koristi zdravila Biktarvy so se pokazale v študijah?
It blocks an enzyme called integrase that is needed by the HIV virus to make new copies of itself in the body.
Zavira encim, imenovan integraza, ki ga virus HIV potrebuje za to, da se v telesu lahko razmnožuje;
Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
Biktarvy (biktegravir/emtricitabin/alafenamidtenofovirat)
Biktarvy is an antiviral medicine used to treat adults infected with human immunodeficiency virus 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Zdravilo Biktarvy je protivirusno zdravilo za zdravljenje odraslih, ki so okuženi z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
Biktarvy does not cure HIV-1 infection or AIDS, but it can hold off damage to the immune system and the development of infections and diseases associated with AIDS.
Zdravilo Biktarvy ne ozdravi okužbe z virusom HIV-1 ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter prepreči razvoj okužb in bolezni, povezanih z aidsom.
The most common side effects with Biktarvy (which may affect around 1 in 20 people) are headache, diarrhoea and nausea (feeling sick).
Najpogostejši neželeni učinki zdravila Biktarvy (ki se lahko pojavijo pri približno 1 bolniku od 20) so glavobol, driska in navzeja (slabost).
• Emtricitabine is another type of NRTI (a nucleoside reverse transcriptase inhibitor) and it works in the same way as tenofovir.
• Emtricitabin je druga vrsta NRTI (nukleotidnega zaviralca reverzne transkriptaze) in deluje enako kot tenofovir.
Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI), which means that it blocks the activity of reverse transcriptase, another enzyme of the virus that allows it to reproduce itself.
tenofovir je nukleotidni zaviralec reverzne transkriptaze (NRTI), kar pomeni, da zavira delovanje reverzne transkriptaze, drugega encima, ki virusu omogoča razmnoževanje.
Biktarvy must not be used together with rifampicin (an antibiotic) or with St. John's wort (a herbal medicine used for treating depression).
Zdravilo Biktarvy se ne sme uporabljati skupaj z rifampicinom (antibiotikom) ali šentjanževko (zdravilom rastlinskega izvora, namenjenim zdravljenju depresije).
Biktarvy can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection.
Predpisovanje in izdaja zdravila Biktarvy je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
Biktarvy is available as tablets, each containing 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.
Ena tableta vsebuje 50 mg biktegravirja, 200 mg emtricitabina in 25 mg alafenamidtenofovirata.
• Bictegravir is a type of antiviral agent called an ‘integrase inhibitor'.
• biktegravir je vrsta protivirusne snovi, imenovane „zaviralec integraze“.
Two studies involved adults infected with HIV-1 who had not been treated previously, and looked at the numbers whose viral load (the amount of HIV-1 in the blood) was reduced to less than 50 copies per ml after 48 weeks of treatment.
V dve študiji so bili vključeni odrasli, ki so bili okuženi z virusom HIV-1 in prehodno še niso bili zdravljeni, pri čemer so proučevali, pri koliko bolnikih se je po 48 tednih zdravljenja virusna obremenitev (količina virusa HIV-1 v krvi) zmanjšala na manj kot 50 kopij na ml.
In the second study, the viral load went above the threshold in 2% (5 out of 290) of patients switched to Biktarvy, and in 2% (5 out of 287) of patients who stayed on their previous treatment (‘boosted' atazanavir or darunavir plus either emtricitabine/tenofovir or abacavir/lamivudine).
V drugi študiji se je virusna obremenitev povečala nad mejno vrednost pri 2 % (5 od 290) bolnikov, ki so prešli na zdravilo Biktarvy, in pri 2 % (5 od 287) bolnikov, ki so ostali pri predhodnem zdravljenju (okrepljeni atazanavir ali darunavir v kombinaciji z emtricitabinom/tenofovirjem ali abakavirjem/lamivudinom).
Overall, 92% of patients taking Biktarvy (290 out of 314) achieved viral load reduction, compared with 93% (293 out of 315) of patients who achieved it with the comparator.
Skupno je zmanjšanje virusne obremenitve doseglo 92 % (290 od 314) bolnikov, ki so prejemali zdravilo Biktarvy, in 93 % (293 od 315) bolnikov, ki so prejemali primerjalno zdravilo.